Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Kura Oncology, Inc. (KURA)
A forensic read on Kura Oncology, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-1.1
Distress distance
Watch
Earnings quality
4
Forensic signals
-2.9
P / E (ttm)
-160.0%
ROE
$844M
Market cap
0.00%
Dividend yield
25.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Kura Oncology, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -1.1, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-50.8%
FY2025
Return on invested capital.Return on invested capital is -50.8% in the latest fiscal year and slipping from -29% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+9.4%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +31% over the last 3 years to FY2025 (+9.4%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~9.4% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~24%.
48d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 14 to 48 days FY2024→FY2025 (receivables +327% vs revenue +25%). Receivables grew, but deferred revenue grew +102% over the same period too — rising alongside rising unearned revenue reads as upfront billing on multi-period contracts, not slipping collections. There's no FY2023 figure on file for receivables, so FY2024 has no opening balance to average against — both figures are measured on period-end balances rather than the beginning-plus-ending average, since averaging only the current year would make the move track balance-sheet growth rather than the business.
55% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 55% of revenue in FY2025 — about $0.42 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 9.6% a year and is falling.
Key fundamentals
Latest Revenue$67.5M
Revenue Growth YoY+25.2%
Net Margin-412.9%
Free Cash Flow-$70.7M
Return on Equity-160.0%
Debt / Equity0.06x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Kura Oncology, Inc.'s actual 10-K/10-Q/8-K filings?